retatrutide clinical trial phase Eli Lilly infiltrates anti-obesity market as III for begins Retatrutide Meets Phase 3 Weight-Loss

3 Takeaways from the Landmark Oral GLP-1 'Switch' Trial for Obesity Care The Weight Maintenance Challenge As clinicians on the front lines of obesity medicine, we are intimately familiar with the central challenge our patients face: sustaining weight loss after a period of initial success

On the other hand, the glucose-lowering effect observed for TH mimetics is believed to be secondary to the beneficial effects of weight loss on insulin sensitivity 14

Nearly 4% of users who reported side effects described reproductive symptoms, including menstrual changes such as intermenstrual bleeding, heavy bleeding and irregular cycles

Patients should examine injection sites for lumps, indentations, redness, or tenderness

Strategic Expansion Creates Future Optionality In addition to advancing its core GLP-1 metabolic disease platform, SureNano Science is also evaluating early-stage opportunities that could broaden the long-term scope of its therapeutic and delivery technology portfolio